{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:39:54Z","timestamp":1790195994854,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to understand 1) factors associated with INH-monoresistant TB and 2) the association between INH monoresistance and response to TB treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied all patients with TB (age, \u226515 yr) reported to the Georgia State Electronic Notifiable Disease Surveillance System (SENDSS) from 2009 to 2014. INH-monoresistant TB was defined as a Mycobacterium tuberculosis isolate resistant to isoniazid only. Time to sputum culture conversion was defined as the time (measured in days) from TB treatment initiation to the date of the first consistently negative culture result reported to the SENDSS. Logistic regression and Cox proportional hazard models were used to estimate the odds and hazard rate of sputum culture conversion, all-cause mortality, and poor TB outcome among patients with INH-monoresistant TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,141 culture-confirmed patients with available drug susceptibility testing results, 998 (87.5%) were susceptible to TB first-line drugs, and 143 (12.5%) were patients with INH-monoresistant TB. In multivariable analysis, male sex (adjusted odds ratio [aOR], 1.62; 95% confidence interval [CI], 1.01\u20132.67) and homelessness (aOR, 5.55; 95% CI, 3.38\u20139.17) were associated with higher odds of INH-monoresistant TB. In the same multivariable model, older age (\u226565 yr old) (aOR, 0.21; 95% CI, 0.07\u20130.55) and miliary disease (aOR, 0.19; 95% CI, 0.01\u20130.96) were associated with lower odds of INH-monoresistant TB. Among 1,116 patients with pulmonary TB, the median time to sputum culture conversion was 30 days (interquartile range, 13\u201358). The rate of culture conversion was similar among patients with and without INH monoresistance (adjusted cause-specific hazard ratio, 1.15; 95% CI, 0.95\u20131.40). INH-monoresistant TB was not significantly associated with poor TB treatment outcomes (aOR, 1.61; 95% CI, 0.67\u20133.70) or mortality during TB treatment (aOR, 1.72; 95% CI, 0.58\u20134.94).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that compared with drug-susceptible TB, patients in Georgia with INH-monoresistant TB have a similar response to TB treatment including culture conversion rate, final TB treatment outcome, and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201702-147oc","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T15:25:37Z","timestamp":1510586737000},"page":"331-340","source":"Crossref","is-referenced-by-count":18,"title":["Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009\u20132014"],"prefix":"10.1093","volume":"15","author":[{"given":"Argita D.","family":"Salindri","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia"},{"name":"Tuberculosis Program, Division of Health Protection, Georgia Department of Public Health, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie F.","family":"Sales","sequence":"additional","affiliation":[{"name":"Tuberculosis Program, Division of Health Protection, Georgia Department of Public Health, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"DiMiceli","sequence":"additional","affiliation":[{"name":"Tuberculosis Program, Division of Health Protection, Georgia Department of Public Health, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C.","family":"Schechter","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Kempker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-5796","authenticated-orcid":false,"given":"Matthew J.","family":"Magee","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2026020502162286000_bib1","article-title":"Global tuberculosis report 2016","author":"World Health Organization","year":"2016"},{"key":"2026020502162286000_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5588\/ijtld.16.0716","article-title":"Isoniazid-resistant tuberculosis: a cause for concern?","volume":"21","author":"Stagg","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026020502162286000_bib3","article-title":"Global tuberculosis report 2014","author":"World Health Organization","year":"2014"},{"key":"2026020502162286000_bib4","doi-asserted-by":"crossref","first-page":"e22927","DOI":"10.1371\/journal.pone.0022927","article-title":"Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994\u20132009","volume":"6","author":"Jenkins","year":"2011","journal-title":"PLoS One"},{"key":"2026020502162286000_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1604544","article-title":"Transmission of extensively drug-resistant tuberculosis in South Africa","volume":"376","author":"Shah","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020502162286000_bib6","article-title":"Reported tuberculosis in the United States, 2015","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"2026020502162286000_bib7","article-title":"2014 Georgia tuberculosis report","author":"Georgia Department of Public Health","year":"2014"},{"key":"2026020502162286000_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.5588\/ijtld.11.0637","article-title":"Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007\u20132009","volume":"16","author":"Gegia","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026020502162286000_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10096-011-1167-4","article-title":"Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis","volume":"30","author":"Fox","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026020502162286000_bib10","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1001\/archinte.168.18.1984","article-title":"Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003","volume":"168","author":"Hoopes","year":"2008","journal-title":"Arch Intern Med"},{"issue":"8","key":"2026020502162286000_bib11","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.8.30467","article-title":"Twenty years and counting: epidemiology of an outbreak of isoniazid-resistant tuberculosis in England and Wales, 1995 to 2014","volume":"22","author":"Smith","year":"2017","journal-title":"Euro Surveill"},{"key":"2026020502162286000_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/595689","article-title":"Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis","volume":"48","author":"Cattamanchi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026020502162286000_bib13","doi-asserted-by":"crossref","first-page":"e0152933","DOI":"10.1371\/journal.pone.0152933","article-title":"Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru","volume":"11","author":"Villegas","year":"2016","journal-title":"PLoS One"},{"key":"2026020502162286000_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/00365548.2011.611169","article-title":"Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patients","volume":"44","author":"Vadwai","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"2026020502162286000_bib15","article-title":"WHO treatment guidelines for drug-resistant tuberculosis 2016 update","author":"World Health Organization","year":"2016"},{"key":"2026020502162286000_bib16","doi-asserted-by":"crossref","first-page":"e86316","DOI":"10.1371\/journal.pone.0086316","article-title":"Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2026020502162286000_bib17","doi-asserted-by":"crossref","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"2026020502162286000_bib18","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"50","author":"Hazbon","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020502162286000_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2334-10-43","article-title":"Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study","volume":"10","author":"Hu","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2026020502162286000_bib20","doi-asserted-by":"crossref","first-page":"c4451","DOI":"10.1136\/bmj.c4451","article-title":"Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study","volume":"341","author":"Vinnard","year":"2010","journal-title":"BMJ"},{"key":"2026020502162286000_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026020502162286000_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/thoraxjnl-2015-208262","article-title":"What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis","volume":"71","author":"Stagg","year":"2016","journal-title":"Thorax"},{"key":"2026020502162286000_bib23","article-title":"2013 Georgia tuberculosis report","author":"Georgia Department of Public Health","year":"2013"},{"key":"2026020502162286000_bib24","article-title":"Georgia tuberculosis reference guide","author":"Georgia Department of Public Health","year":"2014"},{"key":"2026020502162286000_bib25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/jcm.31.4.771-775.1993","article-title":"Current practices in mycobacteriology: results of a survey of state public health laboratories","volume":"31","author":"Huebner","year":"1993","journal-title":"J Clin Microbiol"},{"key":"2026020502162286000_bib26","article-title":"Mycobacteriology lab tests: quick reference sheets","author":"Georgia Department of Public Health","year":"2004"},{"key":"2026020502162286000_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2026020502162286000_bib28","article-title":"Definitions and reporting framework for tuberculosis\u20142013 revision","author":"World Health Organization","year":"2013"},{"key":"2026020502162286000_bib29","article-title":"Survival analysis: a self-learning text, 3rd ed","author":"Kleinbaum","year":"2011"},{"key":"2026020502162286000_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","article-title":"Causal diagrams for epidemiologic research","volume":"10","author":"Greenland","year":"1999","journal-title":"Epidemiology"},{"key":"2026020502162286000_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/ije\/25.6.1107","article-title":"Basic methods for sensitivity analysis of biases","volume":"25","author":"Greenland","year":"1996","journal-title":"Int J Epidemiol"},{"key":"2026020502162286000_bib32","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1371\/journal.pmed.0050188","article-title":"The infectiousness of tuberculosis patients coinfected with HIV","volume":"5","author":"Escombe","year":"2008","journal-title":"PLoS Med"},{"key":"2026020502162286000_bib33","article-title":"Guidance for Industry: Pulmonary tuberculosis: developing drugs for treatment","author":"Food and Drug Administration","year":"2013"},{"key":"2026020502162286000_bib34","article-title":"Treatment of tuberculosis: guidelines for national programmes","author":"World Health Organization","year":"2003"},{"key":"2026020502162286000_bib35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-144-9-200605020-00008","article-title":"Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome","volume":"144","author":"Holtz","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026020502162286000_bib36","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/cid\/cix686","article-title":"Time to sputum culture conversion and treatment outcomes among patients with isoniazid-resistant tuberculosis in Atlanta, Georgia","volume":"65","author":"Schechter","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026020502162286000_bib37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.5588\/ijtld.16.0293","article-title":"Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children","volume":"20","author":"Garcia-Prats","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026020502162286000_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.5588\/ijtld.16.0843","article-title":"Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa","volume":"21","author":"van der Heijden","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026020502162286000_bib39","doi-asserted-by":"crossref","first-page":"e0168955","DOI":"10.1371\/journal.pone.0168955","article-title":"Isoniazid mono-resistant tuberculosis: impact on treatment outcome and survival of pulmonary tuberculosis patients in southern Mexico 1995\u20132010","volume":"11","author":"Baez-Saldana","year":"2016","journal-title":"PLoS One"},{"key":"2026020502162286000_bib40","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00462-15","article-title":"Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs","volume":"59","author":"Lalande","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020502162286000_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.45.4.1302-1304.2001","article-title":"Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials","volume":"45","author":"Wallis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020502162286000_bib42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/ajrccm.156.3.9612016","article-title":"DATRI 008 Study Group. Early bactericidal activity of isoniazid in pulmonary tuberculosis: optimization of methodology","volume":"156","author":"Hafner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502162286000_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1164\/ajrccm.156.3.9609132","article-title":"The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis","volume":"156","author":"Donald","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020502162286000_bib44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/aje\/155.9.866","article-title":"Completeness of notifiable infectious disease reporting in the United States: an analytical literature review","volume":"155","author":"Doyle","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2026020502162286000_bib45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"Treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/3\/331\/66732924\/annalsats_15_3_331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/15\/3\/331\/66732924\/annalsats_15_3_331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:16:55Z","timestamp":1770275815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/15\/3\/331\/8456788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201702-147oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,3,1]]}}}